NCT00437632View on ClinicalTrials.gov

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 1, 2007

Primary Completion Date

August 22, 2008

Study Completion Date

August 22, 2008

Conditions
Substance Dependence
Interventions
DRUG

GSK598809

GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.

DRUG

Placebo

Subjects will receive matching placebo capsules to GSK598809 orally with water.

DRUG

Caffeine

Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00437632 - Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 | Biotech Hunter | Biotech Hunter